Bredehöft Michael, Schänzer Wilhelm, Thevis Mario
Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Carl-Diem-Weg 6, 50933 Cologne, Germany.
Rapid Commun Mass Spectrom. 2008;22(4):477-85. doi: 10.1002/rcm.3388.
Human insulin-like growth factor-1 (IGF-1) is a peptide hormone that acts as a mediator of most of the somatotropic effects of growth hormone (GH). Therefore, it is supposed to be a biomarker indicating GH abuse in sports as well as diseases associated with a change in IGF-1 plasma concentration. It can be applied locally by injection to increase total protein and DNA content in tissues such as skeletal muscle--a highly desirable effect in various sports disciplines. In order to improve its growth-promoting properties, the primary structure of IGF-1 has been modified, yielding analogues such as des(1-3)IGF-1 and LONGR3IGF-1, which show a considerably reduced affinity to the respective binding proteins in plasma and, thus, an increased bioavailability at target tissues. Due to their capability to enhance performance, IGF-1 and its analogues belong to the prohibited list of the World Anti-Doping Agency. Hence, it was necessary to develop a reliable assay for the quantification of human IGF-1 as well as the detection of its derivatives. Immunoaffinity isolation and purification from 60 microL of plasma followed by liquid chromatography/electrospray ionisation tandem mass spectrometry enabled the unequivocal determination of all target analytes. Diagnostic product ions were characterised utilising an Orbitrap mass spectrometer with high resolution/high accuracy properties and employed for triple quadrupole MS/MS analysis. The described assay provided lower limits of detection (LLODs) between 20 and 50 ng/mL, recovery rates between 34-43% and a precision <15% at the LLOD as well as higher concentration levels. In order to prove the applicability of the developed assay, human plasma samples were analysed and the results were compared with the values obtained from a commercially available immunoradiometric assay (IRMA). Four of six samples resulted in concentration ratios with good correlation between both assays, whereas the absolute concentrations were lower for the presented procedure.
人胰岛素样生长因子-1(IGF-1)是一种肽类激素,它是生长激素(GH)大多数促生长作用的介导因子。因此,它被认为是一种生物标志物,可指示体育赛事中生长激素滥用情况以及与IGF-1血浆浓度变化相关的疾病。它可以通过注射局部应用,以增加骨骼肌等组织中的总蛋白和DNA含量——这在各种体育项目中是非常理想的效果。为了改善其促生长特性,IGF-1的一级结构已被修饰,产生了诸如脱(1-3)IGF-1和LONGR3IGF-1等类似物,它们与血浆中相应结合蛋白的亲和力显著降低,因此在靶组织中的生物利用度增加。由于它们具有提高运动表现的能力,IGF-1及其类似物属于世界反兴奋剂机构的禁用清单。因此,有必要开发一种可靠的检测方法来定量人IGF-1及其衍生物。从60微升血浆中进行免疫亲和分离和纯化,然后进行液相色谱/电喷雾电离串联质谱分析,能够明确测定所有目标分析物。利用具有高分辨率/高精度特性的轨道阱质谱仪对诊断产物离子进行表征,并用于三重四极杆MS/MS分析。所描述的检测方法的检测下限(LLOD)在20至50纳克/毫升之间,回收率在34%-43%之间,在LLOD以及更高浓度水平下的精密度<15%。为了证明所开发检测方法的适用性,对人血浆样本进行了分析,并将结果与从市售免疫放射分析(IRMA)获得的值进行了比较。六个样本中有四个样本的浓度比在两种检测方法之间具有良好的相关性,而所提出方法的绝对浓度较低。